BDB-001 injection

DRUG8 trials

Sponsors

Staidson (Beijing) Biopharmaceuticals Co., Ltd

Conditions

ANCA Associated Vasculitis (AAV)ANCA-associated VasculitisCOVID-19COVID-19 PneumoniaHealthyHidradenitis Suppurativa

Phase 1

A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients

TerminatedNCT05075304

Staidson (Beijing) Biopharmaceuticals Co., LtdCOVID-19

Start: 2020-02-21End: 2020-04-14Updated: 2024-05-21

Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

CompletedNCT05103423

Staidson (Beijing) Biopharmaceuticals Co., LtdHidradenitis Suppurativa

Start: 2021-06-24End: 2023-07-07Updated: 2024-03-26

Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis

CompletedNCT05197842

Staidson (Beijing) Biopharmaceuticals Co., LtdANCA-associated Vasculitis

Start: 2022-02-22End: 2025-03-19Updated: 2025-08-07

Tolerability and Safety of BDB-001 Injection in Healthy Subjects

CompletedNCT05361005

Staidson (Beijing) Biopharmaceuticals Co., LtdHealthy

Start: 2020-03-12End: 2020-05-08Updated: 2022-05-04

Safety and Tolerability of BDB-001 Injection in Healthy Subjects

CompletedNCT05360927

Staidson (Beijing) Biopharmaceuticals Co., LtdHealthy

Start: 2019-09-25End: 2020-12-25Updated: 2022-05-04

Phase 2

Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS

TerminatedNCT04449588

Staidson (Beijing) Biopharmaceuticals Co., LtdCOVID-19 Pneumonia

Start: 2020-07-23End: 2024-03-26Updated: 2024-05-22

Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

CompletedNCT05093855

Staidson (Beijing) Biopharmaceuticals Co., LtdHidradenitis Suppurativa

Start: 2021-08-18End: 2023-08-22Updated: 2023-08-29

Phase 3

BDB-001 Phase III Trial in ANCA-Associated Vasculitis

RecruitingNCT07168161

Staidson (Beijing) Biopharmaceuticals Co., LtdANCA Associated Vasculitis (AAV)

Start: 2025-11-10End: 2028-02-29Target: 300Updated: 2026-08-13

Related Papers

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial.

2020-09-28149 citations